Idera Pharmaceuticals Enters into a Clinical Development Support Agreement with Pillar Partners Foundation to Expand the Clinical Research on IMO-2125 beyond PD-1 Refractory Melanoma

You are here: Home » Regional News » Idera Pharmaceuticals Enters into a Clinical Development Support Agreement with Pillar Partners Foundation to Expand the Clinical Research on IMO-2125 beyond PD-1 Refractory Melanoma

Comments are closed.